Actively Recruiting
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Led by AstraZeneca · Updated on 2026-05-13
3000
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
CONDITIONS
Official Title
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with stage I-III non-small cell lung cancer at initial diagnosis
- Aged 18 years or older at first NSCLC diagnosis
- Diagnosed with NSCLC between May 1 and December 31 in 2025, 2026, or 2027
You will not qualify if you...
- NSCLC is not the primary cancer diagnosis
- Recent history of another tumor or concurrent other tumor
- Participating in interventional clinical trials at the time of initial diagnosis
- Positive pregnancy status at the time of diagnosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Research Site
Beijing, China
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here